reported a rather unexpected result, detailing that anti-PD-1 antibody produced objective responses in approximately one in four to one in five patients with non-small-cell lung cancer (NSCLC), melanoma, or renal cell cancer, with tolerable adverse events (AEs) (3). The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.